Aisen Lab

Research focus

NIH R01 · 2025

Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months

Cognition Therapeutics, Inc. (CogRx) is developing CT1812, a disease-modifying drug for Alzheimer’s disease. CT1812 is the first highly brain penetrant selective sigma-2 receptor antagonist small molecule. This drug candidate selectively displaces amyloid-β oligomers bound to neuronal receptors at synapses and protects synapses from toxic oligomer effects, clearing oligomers from the brain into the cerebrospinal fluid. When administered once daily for 28 days to mild to moderate AD patients, CT1812 significantly increases CSF concentration of AβOs, increases plasma concentrations of lipids and metabolites, and reduces concentrations of synaptic degeneration markers in AD patient CSF,…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.